CC vs VRTX · P/E 72, rev $1.36B vs P/E 30, rev $12.00B
Chemours Co (CC) versus Vertex Pharmaceuticals Inc (VRTX) — a side-by-side from cached financials, not a winner call.
Chemours Co (CC) is a specialty chemicals company listed on US.
Vertex Pharmaceuticals Inc (VRTX) is a biotechnology company listed on US.
Latest reported CC revenue for 2024-12-31 was $1.36B. Net income was -$8.0M. Revenue was down 9.9% from 2024-09-30 to 2024-12-31. CC currently screens at market cap $1.94B and trailing P/E 71.8.
Latest reported VRTX revenue for 2025-12-31 was $12.00B. Net income was $3.95B. Revenue was up 8.9% from 2024-12-31 to 2025-12-31. VRTX currently screens at market cap $106.87B and trailing P/E 29.7.
CC currently screens at market cap $1.94B and trailing P/E 71.8. VRTX currently screens at market cap $106.87B and trailing P/E 29.7.
Not investment advice. Open the CC and VRTX stock pages for the full models.
Not investment advice.